HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rai, A. Articles by Gulati, A. Search for Related Content PubMed PubMed Citation Articles by Rai, A. Articles by Gulati, A.

---

CANCER

Effect of the ET_B Receptor Agonist, IRL-1620, on Paclitaxel Plasma Pharmacokinetics of Breast Tumor Rats

Department of Biopharmaceutical Sciences, the University of Illinois at Chicago, Chicago, IL 60612

To whom requests for reprints should be addressed at ¹ Department of Biopharmaceutical Sciences (M/C 865), The University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612. Email: gulati{at}uic.edu

Abstract

Endothelin (ET)-B receptors are expressed in human breast carcinoma. We previously demonstrated that intravenous administration of the ET_B receptor agonist, IRL-1620, to tumor-bearing rats, increased blood perfusion and enhanced delivery of paclitaxel to breast tumor tissue. The present study was conducted to determine whether IRL-1620 alters the pharmacokinetics of paclitaxel. Breast tumor–bearing rats were given 0.3 ml/kg saline or 3 nmol/kg IRL-1620 by intravenous (iv) administration. Fifteen minutes after saline or IRL-1620, 40 µCi/rat ³H-Paclitaxel was administered iv and serial plasma samples were collected until 24 hrs. ³H-Paclitaxel radioactivity in the plasma samples was measured by liquid scintillation counting. Data were fit to a three-compartment model and pharmacokinetic parameters were generated using WinNonlin software. IRL-1620 did not produce any change in the plasma paclitaxel pharmacokinetics of tumor-bearing rats. The AUC_0– (9.43 ± 3.18 µg-hr/ml), clearance (0.69 ± 0.17 l/hr/kg), volume of distribution (10.31 ± 4.54 l/kg), and half-life (1.0 ± 0.32 hrs) of paclitaxel were similar between rats treated with saline or IRL-1620. In conclusion, the ET_B receptor agonist, IRL-1620, does not alter paclitaxel plasma pharmacokinetics and, therefore, could be used to augment the delivery of paclitaxel to the tumor tissue.

Key Words: ET_B receptor agonist • IRL-1620 • drug delivery • pharmacokinetics • paclitaxel